BIOGEN INC. Business Combination, Contingent Consideration, Liability, Current
BIOGEN INC. (BIIB) had Business Combination, Contingent Consideration, Liability, Current of $148.60 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-02-06
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $148.60M.
- 2025-06-30: Business Combination, Contingent Consideration, Liability, Current $297.20M.
- 2025-03-31: Business Combination, Contingent Consideration, Liability, Current $294.30M.
- 2024-12-31: Business Combination, Contingent Consideration, Liability, Current $291.20M.
| Period end | Business Combination, Contingent Consideration, Liability, Current | Business Combination, Contingent Consideration, Liability, Current as first filed |
|---|---|---|
| 2025-09-30 | $148.60M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $297.20M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $294.30M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $291.20M 10-K · filed 2026-02-06 | |
| 2024-09-30 | $287.10M 10-Q · filed 2024-10-30 | |
| 2023-12-31 | $0.00 10-Q · filed 2024-10-30 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-10-20 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-07-22 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-22 | |
| 2020-12-31 | $149.60M 10-Q · filed 2021-10-20 | |
| 2020-09-30 | $164.40M 10-Q · filed 2020-10-21 | |
| 2020-06-30 | $149.10M 10-Q · filed 2020-07-22 | |
| 2020-03-31 | $147.30M 10-Q · filed 2020-04-23 | |
| 2019-12-31 | $148.40M 10-Q · filed 2020-10-21 | |
| 2019-09-30 | $147.50M 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $146.20M 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $147.30M 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $444.80M 10-K · filed 2020-02-06 | |
| 2018-09-30 | $381.50M 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $529.40M 10-Q · filed 2018-07-24 | |
| 2018-03-31 | $524.30M 10-Q · filed 2018-04-24 | |
| 2017-12-31 | $844.60M 10-K · filed 2019-02-06 | |
| 2017-09-30 | $611.50M 10-Q · filed 2017-10-24 | |
| 2017-06-30 | $580.70M 10-Q · filed 2017-07-25 | |
| 2017-03-31 | $516.80M 10-Q · filed 2017-04-25 | |
| 2016-12-31 | $580.80M 10-K · filed 2018-02-01 | |
| 2016-09-30 | $570.50M 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $556.70M 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $505.10M 10-Q · filed 2016-04-21 | |
| 2015-12-31 | $504.70M 10-K · filed 2017-02-02 | |
| 2015-09-30 | $479.50M 10-Q · filed 2015-10-21 | |
| 2015-06-30 | $493.50M 10-Q · filed 2015-07-24 | |
| 2015-03-31 | $64.40M 10-Q · filed 2015-04-24 | |
| 2014-12-31 | $265.50M 10-K · filed 2016-02-03 | |
| 2014-09-30 | $219.30M 10-Q · filed 2014-10-22 | |
| 2014-06-30 | $185.70M 10-Q · filed 2014-07-23 | |
| 2013-12-31 | $54.00M 10-K · filed 2015-02-04 | $29.00M 10-Q · filed 2014-07-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |